BioArctic Announces New Nomination Committee for 2027 Annual Meeting

BioArctic Implements New Nomination Committee for Upcoming Meeting

BioArctic AB (publ), a leading biopharmaceutical company based in Sweden and publicly traded on Nasdaq Stockholm under the ticker BIOA B, has officially announced the formation of its Nomination Committee in preparation for the 2027 Annual General Meeting (AGM). This decision is in line with principles outlined during the previous AGM, ensuring that the committee comprises key stakeholders with significant voting power.

The Nomination Committee will consist of representatives from BioArctic’s three largest shareholders by voting rights as of September 30, 2026. The appointed members include:

- Margareta Öhrvall, representing Demban AB
- Pär Gellerfors, representing Ackelsta AB
- Thomas Ehlin, the Chair of the Nomination Committee, representing Fjärde AP-fonden

Collectively, these shareholders control approximately 57% of the company's total shares and an impressive 82% of voting rights, marking a significant representation that aims to ensure the future direction and governance of BioArctic align with shareholder interests.

The directives and guidelines for the Nomination Committee have been made accessible for shareholders through BioArctic's official website, providing transparency and an opportunity for direct input into the nomination process. Shareholders interested in proposing candidates for the committee are encouraged to submit their suggestions via email at [email protected], or by mailing it to BioArctic AB, Attn: Nomination Committee, Warfvinges väg 35, SE-112 51 Stockholm, Sweden. The deadline to submit proposals is January 15, 2027.

BioArctic has also set the date for its 2027 AGM, which is scheduled for Thursday, May 27, 2027, at 4:30 PM CEST in Stockholm. To facilitate meaningful shareholder involvement, any requests to include specific topics in the meeting agenda should be received by April 15, 2027.

BioArctic is renowned for its innovative approaches to addressing neurodegenerative diseases, being the pioneering force behind Leqembi® (lecanemab), the world’s first drug proven to slow the progression of Alzheimer's disease. The company's focus on research and development in this critical area includes projects utilizing proprietary technologies like BrainTransporter™ for overcoming therapeutic barriers.

For ongoing updates and additional inquiries, stakeholders can reach out to Oskar Bosson, Chief Investor Relations & Communications Officer, or Jenny Ljunggren, Manager of External Communications and Investor Relations, through BioArctic's provided contact details.

As BioArctic continues to advance its mission in innovative biopharmaceutical solutions, the formation of a robust Nomination Committee signifies its commitment to strategic governance and shareholder engagement.